Medical Device Global Market Access

This episode explores Mexico's medical device market through a profile of Medical Prado, a leading distributor for medical imaging and radiology equipment. We analyze their role as an authorized Mindray dealer, the value-added services they provide, and their strategic focus on key regions like CDMX, Edomex, and Jalisco. This case study offers crucial insights for MedTech manufacturers aiming to understand the importance of local distribution partnerships for successful market entry in Mexico. - Who is Medical Prado and what role do they play in Mexico's MedTech scene? - What services do top distributors offer beyond just selling equipment? - Which key regions in Mexico are crucial for medical device sales? - How does partnering with a local distributor impact a market entry strategy? - What can the Mindray-Medical Prado partnership teach us about penetrating the Mexican imaging market? - Which medical specialties are being targeted by leading distributors in Mexico? - Why is a strong local partner essential for navigating regulatory and logistical challenges? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, streamlining global market access with a blend of local expertise and advanced AI. Our services cover the entire product lifecycle, from market access strategy and technical dossier submissions to post-market surveillance. By acting as your local representative in over 30 markets and leveraging technology-driven efficiency, we help you navigate complex regulatory landscapes. Whether you're a startup or a multinational, Pure Global provides tailored solutions to get your products to market faster. Explore our FREE AI tools and database at https://pureglobal.ai, visit our website at https://pureglobal.com/, or contact us at [email protected].

This episode explores the strategic advantages of partnering with specialized local distributors to enter Mexico's medical imaging and radiology market. We analyze the case of XRG Especialidades Médicas, a distributor with over 25 years of experience, to understand how their model of providing turnkey solutions, sales, and after-sales service helps foreign manufacturers navigate regulatory complexities with COFEPRIS and achieve sustainable market penetration. - What makes Mexico an attractive market for medical imaging devices? - How can foreign manufacturers navigate the complexities of COFEPRIS regulations? - What is the strategic role of a local distributor beyond simple sales? - Why is after-sales support and maintenance critical for success in Mexico? - What are the benefits of a "turnkey" solution for hospitals and clinics? - How does partnering with a specialized distributor like XRG de-risk market entry? - What specific product areas, like ultrasound and general radiology, are in demand? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies seeking to enter complex global markets. We streamline market access by acting as your local representative and developing efficient regulatory strategies for over 30 countries. Our advanced AI and data tools accelerate the compilation and submission of technical dossiers, helping you navigate authorities like COFEPRIS with greater speed and accuracy. Whether you're a startup or a multinational, Pure Global provides the local expertise and technology-driven solutions to get your product to market faster. Contact us at [email protected], visit https://pureglobal.com, or explore our FREE AI tools at https://pureglobal.ai.

This episode explores the intricacies of Mexico's medical imaging and radiology market. We focus on the crucial role of local distributors by examining IMADINE, an authorized partner for global giants like Agfa and Philips. We discuss their portfolio, which includes ultrasound, X-ray, CT, and MRI equipment, and their value-added services such as site selection support and procurement assistance for Mexican healthcare facilities. This is a must-listen for any MedTech manufacturer considering entry or expansion into the Mexican market. - How can MedTech companies successfully enter Mexico's complex medical imaging market? - What makes a local distributor like IMADINE essential for brands such as Agfa and Philips? - What are the primary types of imaging equipment in demand within Mexican hospitals? - Beyond sales, what critical support services do local partners provide for radiology departments? - How does the procurement process for high-value medical devices work in Mexico? - What are the key factors to consider when upgrading imaging modalities in this market? - Why is a local presence critical for navigating regulatory and commercial hurdles in Mexico? Navigating a new market like Mexico requires deep local expertise. Pure Global accelerates your market access with end-to-end regulatory consulting for MedTech and IVD firms. We act as your local representative in over 30 markets, including Mexico, developing efficient regulatory strategies and using advanced AI to compile and manage your technical submissions. Let us handle the complexities of global registration so you can focus on growth. To learn how we can streamline your entry into the Americas and beyond, visit us at https://pureglobal.com/, contact [email protected], or explore our FREE AI tools and database at https://pureglobal.ai.

This episode explores the strategic nuances of entering Mexico's orthopedic and trauma medical device market. We analyze the successful distribution model of DAONSA Implantes, a key player that partners with global brands like ConMed and Enovis. We discuss how their focus on specialized clinical support, surgeon education, and workflow integration provides a powerful blueprint for foreign manufacturers seeking to penetrate and thrive in the complex Mexican healthcare landscape. - What makes Mexico a critical market for orthopedic device expansion? - How does a specialized distributor like DAONSA Implantes create value beyond logistics? - Why is in-person case coverage essential for complex surgical devices? - How does aligning products with surgeon workflows accelerate market adoption? - What are the key lessons for partnering with distributors in Latin America? - How do global brands like ConMed and Enovis leverage local partnerships for success? - What should you look for in a medical device distribution partner in Mexico? Pure Global offers end-to-end solutions for MedTech and IVD companies aiming to enter over 30 global markets, including Mexico. We act as your local representative, develop efficient regulatory strategies, and use advanced AI to compile and submit technical dossiers. Our deep local expertise, supported by a global network, ensures you can navigate complex regulatory environments and connect with ideal partners to accelerate your market entry. Let us help you turn a single registration into access across multiple markets. Visit us at https://pureglobal.com/, contact [email protected], or explore our FREE AI tools and database at https://pureglobal.ai.

This episode explores the strategic importance of local partnerships for medical device market access in Mexico, using orthopedic and trauma device distributor IMTRA as a case study. We discuss the role of the Mexican regulatory authority, COFEPRIS, the necessity of holding local registrations, and how a specialized distributor provides essential commercial and technical support to succeed in this key Latin American market. Key Questions - What is COFEPRIS and why is it critical for selling medical devices in Mexico? - How can a foreign manufacturer enter the Mexican orthopedic device market? - What is the role of an exclusive local distributor like IMTRA? - Who typically holds the product registration in Mexico, the manufacturer or the distributor? - Why is local technical and commercial support vital for surgical implants? - How do international standards like ISO and CE marking impact COFEPRIS registration? - What are osteosynthesis implants and what market do they serve? Navigating the complexities of global markets like Mexico requires deep local expertise and a streamlined regulatory approach. Pure Global offers end-to-end solutions for MedTech and IVD companies, acting as your local representative in over 30 markets, including Mexico. We develop efficient regulatory strategies and use advanced AI to compile and submit your technical dossier to authorities like COFEPRIS. Let us help you identify the best markets for expansion and manage your registrations, ensuring you get your products to patients faster. Contact Pure Global at [email protected], visit https://pureglobal.com, or explore our FREE AI tools and database at https://pureglobal.ai.

This episode explores Mexico's dynamic orthopedic and trauma device market, detailing its significant growth drivers, including medical tourism and an expanding private healthcare sector. We provide a clear overview of the regulatory landscape managed by COFEPRIS, including device classification, the crucial role of a Mexican Registration Holder (MRH), and the equivalency pathway for faster market access. We also highlight the indispensable role of experienced local distributors, using the 40-year history of OHISA as a case study in providing essential products and in-OR technical support. - What are the key economic drivers behind Mexico's orthopedic device market growth? - How does COFEPRIS classify medical devices for market approval? - Why is appointing a Mexican Registration Holder (MRH) mandatory for foreign manufacturers? - What is the equivalency pathway and how can it accelerate market entry in Mexico? - What recent regulatory updates took effect on July 10, 2023? - What essential services do local distributors like OHISA provide beyond logistics? - How does medical tourism from the U.S. impact demand for orthopedic implants in Mexico? - What are the main challenges when submitting a technical dossier to COFEPRIS? Pure Global offers expert regulatory consulting solutions for MedTech and IVD companies seeking to enter or expand in over 30 global markets, including Mexico. We act as your local representative, develop efficient regulatory strategies, and use advanced AI to compile and submit technical dossiers, helping you navigate complex landscapes like COFEPRIS with confidence. Our integrated approach streamlines the registration process, allowing a single submission to unlock multiple markets. For strategic guidance on market access, contact us at [email protected], visit our website at https://pureglobal.com, or explore our free AI tools and databases at https://pureglobal.ai.

This episode examines the strategic importance of specialized local distributors for medical device market access, using DPM Distribuidores de Productos Médicos in Mexico as a case study. We explore how DPM's focus on interventional cardiology and radiology provides a crucial advantage for manufacturers entering the complex Mexican healthcare market. - Why is a specialized distributor essential for niche medical devices? - What specific clinical areas does DPM focus on in Mexico? - How can a local partner accelerate market entry for interventional cardiology devices? - What are the benefits of working with a distributor that understands hemodynamics and endovascular materials? - How does a distributor's logistics network impact cath labs and IR services? - What challenges do MedTech companies face when entering the Mexican market alone? - How is DPM evolving its business model to offer integrated solutions? - What should you look for in a medical device distribution partner in Latin America? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, streamlining global market access with local expertise and advanced AI tools. Whether you need a local representative in Mexico for your cardiology device, help compiling a technical dossier for submission, or post-market surveillance, our team can help. We act as your local representative in over 30 markets, developing efficient regulatory strategies to get your product approved faster. To learn more about how we can accelerate your global expansion, visit us at https://pureglobal.com, contact [email protected], or explore our FREE AI tools and database at https://pureglobal.ai.

This episode explores Mexico's advanced medical device market through a case study of Endomédica, a leading distributor in interventional cardiology and radiology. We analyze how their specialized focus, clinical support, and integrated solutions model make them a key player and an ideal partner for international manufacturers seeking to enter the dynamic Latin American market. - What makes Mexico a strategic market for advanced medical devices? - How does a specialized distributor operate in the interventional cardiology space? - What are image-guided therapeutics and why are they a growing field? - Why is clinical support crucial when distributing complex medical devices? - What are the key advantages of partnering with a local expert in Mexico? - How can international manufacturers effectively penetrate the Mexican cath lab market? - What role does a company like Endomédica play in the healthcare ecosystem? Struggling to enter new markets like Mexico? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies. We act as your local representative in over 30 markets, developing efficient regulatory strategies and using advanced AI to compile technical dossiers for submission. Our market research helps you identify the best opportunities, connecting you with key players and streamlining your path to approval. Let us handle the complexities of global market access so you can focus on innovation. Contact us at [email protected], visit https://pureglobal.com, or explore our FREE AI tools and database at https://pureglobal.ai.

This episode explores the lucrative Mexican market for interventional cardiology and radiology devices, detailing the COFEPRIS registration process. We cover the mandatory appointment of a Mexico Registration Holder (MRH), device classification, and the critical differences between the standard and expedited Equivalency Pathways. Learn how leveraging prior approvals from the US, Canada, or Japan can fast-track your market entry and what key regulatory changes are coming in 2025. - What is COFEPRIS and what is its role in Mexico? - Why is a Mexico Registration Holder (MRH) essential for foreign manufacturers? - How does Mexico classify medical devices based on risk? - What is the Equivalency Pathway and how can it speed up registration? - Can my existing FDA or Health Canada approval help me enter the Mexican market? - What are the documentation and language requirements for a COFEPRIS submission? - What significant regulatory update is happening on September 1, 2025? - How long is a medical device registration valid in Mexico? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, acting as your local representative in over 30 markets, including Mexico. We develop efficient pathways for COFEPRIS approval by leveraging your existing registrations and using advanced AI to compile and submit your technical dossier. Our team of local experts provides continuous regulatory monitoring to ensure your market presence is maintained. To learn how we can help your company access the global market faster, visit us at https://pureglobal.com/, contact [email protected], or explore our FREE AI tools and database at https://pureglobal.ai.

This episode explores Brazil's lucrative dental device market, highlighting the critical role of established local distributors for successful market entry. We focus on Dental Speed, a principal distributor founded in 1996, as a case study to understand how strategic partnerships are essential for navigating Brazil's complex regulatory landscape, managed by ANVISA, and achieving commercial success through effective sales channels like e-commerce and telesales. - Why is Brazil a critical market for dental device manufacturers? - Who is Dental Speed and what is their role in the Brazilian dental industry? - What challenges do foreign manufacturers face when entering Brazil? - How does a strong distribution partner help navigate ANVISA regulations? - What makes an e-commerce and telesales model so effective in Brazil? - What types of products are in high demand in the Brazilian dental sector? - How can you leverage a distributor to reach dental practices and labs across the country? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, streamlining global market access. We act as your local representative in over 30 markets, including Brazil, and use advanced AI to develop efficient regulatory strategies and compile technical dossiers for submission to authorities like ANVISA. Our integrated approach combines local expertise with data-driven tools to get your products to market faster. To learn how Pure Global can accelerate your expansion, visit us at https://pureglobal.com, contact [email protected], or explore our FREE AI tools and database at https://pureglobal.ai.

This episode provides a deep dive into Dental Cremer, a Henry Schein company, and its dominant role in the Brazilian dental device market. We explore how its massive e-commerce platform, sophisticated nationwide logistics, and unique financing options create a powerful distribution channel. For international MedTech manufacturers, understanding Dental Cremer's strategy is crucial for successfully navigating market entry and expansion in Latin America's largest economy. Key Questions: - Who is Dental Cremer and how did it become Latin America’s largest dental distributor? - What role does Henry Schein's ownership play in Dental Cremer's market strategy? - How does their e-commerce and logistics model solve key challenges for foreign manufacturers? - What makes Brazil's dental market an attractive but complex target for expansion? - How can device companies leverage a distributor like Dental Cremer to accelerate market penetration? - What are the key services Dental Cremer offers that benefit both clinics and suppliers? Navigating complex markets like Brazil requires expert guidance. Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, streamlining global market access. We act as your local representative in over 30 markets, including Brazil, developing efficient regulatory strategies and compiling technical dossiers using advanced AI. Our team helps you identify the best markets for expansion and ensures ongoing compliance once your product is launched. To learn how we can accelerate your entry into Latin America and beyond, contact Pure Global at [email protected], visit us at https://pureglobal.com, or explore our free AI tools and database at https://pureglobal.ai.

This episode explores Brazil's rapidly growing diagnostic imaging market, a key area for global MedTech companies like Philips Healthcare. We analyze the market's projected growth to USD 1.73 billion by 2030, the primary drivers behind this expansion, and the significant impact of ANVISA's June 2024 regulatory changes, which now recognize approvals from the US, Canada, Japan, and Australia. The discussion covers the opportunities and persistent challenges, such as import dependency and the demand for digital and portable imaging solutions in this dynamic Latin American market. - Why is Brazil's diagnostic imaging market set to grow at over 5.6% annually? - How does ANVISA's June 2024 mutual recognition agreement impact device registration times? - What are the main drivers for imaging equipment demand in Brazil? - Which challenges do foreign manufacturers face when entering the Brazilian market? - What opportunities exist for companies specializing in portable and AI-driven imaging devices? - How are major players like Philips and Siemens adapting to local market needs? - What role does digital transformation play in Brazil's healthcare system? Pure Global offers expert, end-to-end regulatory consulting to help MedTech and IVD companies navigate complex markets like Brazil. By combining local expertise with advanced AI tools, we streamline the path to market access. Our services include developing regulatory strategies, acting as your in-country representative, and using AI to efficiently compile technical dossiers for submission. Let us help you turn regulatory hurdles into market opportunities. Contact us at [email protected], visit our website at https://pureglobal.com, or explore our free AI tools and database at https://pureglobal.ai to accelerate your global expansion.

This episode explores Siemens Healthineers' significant role in Brazil's diagnostic imaging market. We cover their extensive portfolio of CT, MR, angiography, and ultrasound systems, their strategic expansion into diverse regions of the country, and their focus on integrating advanced technologies like Artificial Intelligence. Learn about specific innovations for radiology and cardiology, such as the AI-Rad Companion and the TrueFusion imaging system for complex cardiac procedures. - How is Siemens Healthineers impacting Brazil's diagnostic imaging market? - What specific technologies are they deploying for radiology and cardiology? - What is the role of Artificial Intelligence in their latest imaging systems? - How does their portfolio, including CT, MR, and ultrasound, meet local needs? - What was the significance of their major 2011 deal with the Alliar group? - How does integrating X-ray and echocardiography improve cardiac procedures? - What is the AI-Rad Companion and how does it support radiologists? - How does Siemens Healthineers maintain a strong local presence in Brazil? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, streamlining global market access with local expertise and advanced AI tools. We act as your local representative in over 30 markets, develop efficient regulatory strategies, and use AI to compile and submit technical dossiers. Our powerful data tools aggregate global regulatory news and analyze clinical data to help you identify the best markets for expansion. To learn how we can help your company access global markets faster, contact us at [email protected], visit our website at https://pureglobal.com, or explore our FREE AI tools and database at https://pureglobal.ai.

This episode delves into GE HealthCare's strategic investment in Brazil, examining the establishment of its first diagnostic imaging manufacturing facility in South America. We explore the timeline, from the 2008 announcement to the 2010 factory opening in Contagem, and analyze the "In Latin America, For Latin America" initiative. The discussion covers the types of equipment produced, such as X-ray, CT, and MRI systems, and the broader impact on the Brazilian healthcare market, including increased access to affordable technology and local workforce development. This case study provides key insights for MedTech companies on navigating emerging markets through localization. - Why did GE HealthCare target Brazil for its first manufacturing facility in South America? - What was the timeline of GE HealthCare's investment in Brazilian manufacturing? - Which specific diagnostic imaging devices were initially produced at the Brazil factory? - What was the "In Latin America, For Latin America" initiative? - How did local production impact the cost and accessibility of medical devices in Brazil? - Beyond manufacturing, how did GE HealthCare invest in the local Brazilian ecosystem? - What were the long-term goals for product development at the Contagem facility? - How does localizing production help MedTech companies overcome market access barriers? - What role did partnerships play in GE HealthCare's strategy? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, leveraging local expertise and advanced AI to streamline global market access. We act as your local representative in over 30 markets, developing efficient regulatory strategies and using AI to compile and submit technical dossiers. Our services ensure your product gets to market faster while maintaining compliance through post-market surveillance and continuous regulatory monitoring. Whether you are a startup or a multinational enterprise, our integrated approach allows a single registration process to unlock multiple international markets. Contact us at [email protected] or visit https://pureglobal.com and https://pureglobal.ai for FREE AI tools.

This episode examines the Brazilian market for orthopedic medical devices, using DePuy Synthes (a J&J MedTech company) as a case study. We break down the essential regulatory requirements set by ANVISA, including the pivotal RDC 751/2022 resolution, device classification, the mandatory Brazilian Registration Holder (BRH), and Good Manufacturing Practice (B-GMP) certification. Learn how a global leader successfully navigates one of Latin America's most challenging yet rewarding markets. Key Questions: - What is ANVISA's role in regulating orthopedic devices in Brazil? - How does the RDC 751/2022 resolution impact medical device registration? - What are the four risk classes for medical devices in Brazil, and why do they matter? - Why is a Brazilian Registration Holder (BRH) essential for foreign manufacturers? - What is required to achieve Brazilian Good Manufacturing Practice (B-GMP) certification? - How does DePuy Synthes manage its extensive orthopedic portfolio in the Brazilian market? - Can registration from the US FDA or Health Canada speed up ANVISA approval? - What are the key strategic components for succeeding in Brazil's MedTech sector? Pure Global offers expert regulatory consulting for MedTech and IVD companies, streamlining global market access with local expertise and advanced AI tools. From initial strategy and technical dossier submissions to acting as your local representative in over 30 markets, we cover the entire product lifecycle. Our technology-driven approach ensures efficiency and accuracy for startups and multinational enterprises alike. To learn how we can accelerate your entry into markets like Brazil, visit us at https://pureglobal.com/, contact [email protected], or explore our FREE AI tools and database at https://pureglobal.ai/.

This episode explores the strategic pathway for medical device market entry into Brazil, the largest MedTech market in Latin America. We analyze the case of Zimmer Biomet Brasil Ltda. to illustrate the critical importance of establishing a local subsidiary, securing a Brazil Registration Holder (BRH), and navigating the complex regulatory landscape governed by ANVISA, including requirements like Brazilian Good Manufacturing Practice (BGMP) and INMETRO certification. - What makes Brazil an attractive yet challenging market for device manufacturers? - Why can't foreign companies directly register devices with Brazil's ANVISA? - What is a Brazil Registration Holder (BRH) and why is it essential? - How does a company's corporate structure, like its CNAE code, impact operations in Brazil? - What are the key steps in the ANVISA registration process? - Are on-site inspections for Brazilian Good Manufacturing Practice (BGMP) always required? - When is an INMETRO certification necessary for medical devices? - How did Zimmer Biomet structure its Brazilian subsidiary for success? Pure Global offers end-to-end regulatory consulting solutions for MedTech and IVD companies, combining local expertise with advanced AI to streamline global market access. We act as your local representative in over 30 markets, developing efficient pathways for regulatory approval. Our AI-powered tools help compile and submit technical dossiers, while our team provides continuous monitoring of regulatory changes. For startups to multinational enterprises, we provide scalable solutions. Learn more about accessing markets like Brazil faster at https://pureglobal.com/, contact us at [email protected], or explore our FREE AI tools and database at https://pureglobal.ai.

This episode examines Stryker do Brasil's successful strategy for dominating the Brazilian orthopedics market. We explore their extensive national distributor network, the specific product lines covered, and how their transparent, service-oriented approach provides crucial support to surgical teams, offering a powerful case study for medical device manufacturers looking to penetrate complex international markets. Key Questions: - How does a MedTech giant like Stryker structure its distribution in a market as complex as Brazil? - What specific orthopedic product lines are managed through this national network? - Why is a public list of distributors a strategic advantage for Stryker do Brasil? - How does Stryker provide more than just logistics, directly supporting surgical teams? - What lessons can other device manufacturers learn from Stryker's approach to market access in Brazil? - What role does a local hub play in managing a nationwide distributor network? - How can a well-organized distribution strategy accelerate market penetration? Navigating a complex regulatory landscape like Brazil's is a significant challenge. Pure Global provides MedTech and IVD companies with end-to-end solutions to accelerate global market access. We act as your local representative in over 30 markets, including Brazil, developing efficient regulatory strategies and using advanced AI to compile and submit technical dossiers. Our market research helps you select the best regions for expansion. Let us handle the complexities of global registration so you can focus on innovation. Contact us at [email protected], visit https://pureglobal.com, or explore our FREE AI tools and database at https://pureglobal.ai.

This episode explores the lucrative but complex medical device market in Brazil, the largest in Latin America. Using Abbott's Cardiac Rhythm Management (CRM) division as a practical example, we break down the critical regulatory requirements for high-risk devices. We cover the role of the national authority, ANVISA, the essential RDC 751/2022 regulation, the mandatory Brazilian Registration Holder (BRH) system, and the stringent Brazilian Good Manufacturing Practice (B-GMP) certification. We also discuss the game-changing new 'Reliance' pathway introduced in June 2024, which allows leveraging approvals from agencies like the US FDA to expedite market entry. - What makes Brazil such an attractive market for MedTech companies? - Who is ANVISA and what is their role in medical device approval? - What are the key requirements under the RDC 751/2022 regulation? - Why is a Brazilian Registration Holder (BRH) essential for foreign manufacturers? - What is involved in obtaining a Brazilian GMP (B-GMP) certificate for a Class III or IV device? - How does ANVISA's new 'Reliance' route, effective June 2024, change the game for market access? - What lessons can be learned from Abbott's strategy for distributing pacemakers and ICDs in Brazil? - What are the specific language requirements for labeling in Brazil? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, streamlining global market access. We act as your local representative in over 30 markets, including Brazil, developing efficient regulatory strategies and using advanced AI to compile technical dossiers. Our experts navigate complex requirements like ANVISA's RDC 751/2022 and B-GMP certification, while our new AI tools help you monitor regulatory changes. Whether you're a startup or a multinational, we accelerate your path to market. Contact Pure Global at [email protected], visit https://pureglobal.com, or explore our FREE AI tools and database at https://pureglobal.ai.

This episode explores the strategic approach of Boston Scientific in the Brazilian medical device market, focusing on its cardiology and electrophysiology operations. We analyze how Boston Scientific do Brasil functions as a local wholesale trader, supports key product portfolios like stents and balloons, and leverages global resources for physician education and supply chain continuity. Learn how this multinational giant combines local presence with global strength to succeed in Brazil's complex healthcare landscape. Key Questions: - How does a major multinational like Boston Scientific structure its operations in Brazil? - What specific cardiology and electrophysiology products are central to their Brazilian strategy? - What is the official role of Boston Scientific do Brasil within the local market? - How does the company ensure supply continuity and field service for Brazilian hospitals? - Why is physician education a critical component of their market access plan? - How do they balance local entity management with leveraging global product lines? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, streamlining your path to international markets. Our unique approach combines local expertise in over 30 countries with advanced AI and data tools for efficient technical dossier preparation, regulatory strategy, and market selection. We act as your local representative, manage post-market surveillance, and ensure continuous compliance. Whether you're a startup or a multinational, Pure Global provides the solutions to access global markets faster. Contact us at [email protected], visit https://pureglobal.com, or explore our FREE AI tools and database at https://pureglobal.ai.

This episode analyzes how Medtronic has achieved long-term success in Brazil's complex cardiology device market. We explore their strategy of combining product distribution with extensive clinical support and training to navigate regulatory hurdles and a dual healthcare system, a model established since their entry in 1971. - How did Medtronic build a 50-year legacy in the Brazilian cardiology market? - What is the role of a local subsidiary in navigating ANVISA's regulations? - Why is clinical training as critical as sales for market access in Brazil? - How does the dual public-private healthcare system in Brazil impact device strategy? - What are the key products in Medtronic's Brazilian cardiology portfolio? - How can foreign device manufacturers overcome the shortage of skilled clinicians? - What makes Brazil a challenging yet rewarding market for medical devices? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, streamlining global market access. We act as your local representative in over 30 markets, developing efficient regulatory strategies and using advanced AI to compile and submit technical dossiers. Our integrated approach allows a single registration process to access multiple markets, supported by local experts on five continents. Whether you're a startup or a multinational, Pure Global provides the solutions to get your product approved and maintain compliance. Contact us at [email protected], visit https://pureglobal.com, or explore our FREE AI tools at https://pureglobal.ai.

This episode breaks down the core components of a successful global market access strategy for MedTech and IVD companies. We explore the importance of building a proactive regulatory roadmap, the challenges of tailoring technical dossiers for different international markets like the US, EU, and Asia, and the critical role of local representation and post-market surveillance in maintaining compliance. Learn how modern AI-driven tools can streamline submissions and help you navigate the complex web of global regulations to expand your market reach efficiently. - What are the foundational elements of a global regulatory strategy? - How can you leverage a single technical dossier for multiple country submissions? - Why is an in-country representative essential for market access and maintenance? - What are the key post-market surveillance responsibilities you cannot ignore? - How is AI technology transforming the process of regulatory submissions? - What are the strategic differences when targeting markets in the Americas versus the EU or Asia? - How can you avoid common pitfalls that delay international product registration? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, streamlining global market access. We combine local expertise from over 15 offices on five continents with advanced AI to manage the entire product lifecycle. From initial market research and regulatory strategy to technical dossier submission and post-market surveillance, our integrated approach allows for a single process to access over 30 markets. We act as your local representative, ensuring continuous compliance. Contact us at [email protected], visit https://pureglobal.com, or explore our FREE AI tools and database at https://pureglobal.ai.

This episode delves into McKesson's major announcement from May 2025 to spin off its Medical-Surgical Solutions (MMS) division into a new, independent company. We explore the strategic rationale behind this decision and what it means for the US medical device distribution landscape. We analyze the specific role of MMS in serving alternate-site providers like physician offices and surgery centers and discuss the significant implications this separation will have for MedTech manufacturers focused on the non-acute care market. - What is McKesson's plan for its Medical-Surgical Solutions division starting in 2025? - Why is one of the largest healthcare distributors making this strategic change? - What are "alternate-site providers" and why are they a crucial market? - How will the new independent company ("NewCo") be different from the current MMS? - What opportunities does this spin-off create for medical device manufacturers? - If your products are sold to clinics or for home use, how does this affect your distribution strategy? - What is the projected timeline for the completion of this separation? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, streamlining global market access with a unique blend of local expertise and advanced AI. Our services cover every stage, from initial regulatory strategy and technical dossier submissions to acting as your local representative in over 30 markets. We help you identify the best markets, achieve faster approvals, and maintain compliance post-market. By integrating a single registration process across multiple countries, we offer unparalleled efficiency. Contact us at [email protected], visit https://pureglobal.com/, or explore our FREE AI tools and database at https://pureglobal.ai.

This episode provides a detailed analysis of Cardinal Health's Global Medical Products & Distribution (GMPD) segment, a dominant force in the U.S. medical supply market. We explore its business model, recent financial performance through FY2024 and FY2025, and its strategic importance for healthcare providers. The discussion covers how its private-label brands and national logistics network make it a top-tier distribution partner for cost-conscious and quality-focused sourcing strategies in 2025. Key Questions: - What makes Cardinal Health's GMPD segment a leader in U.S. medical distribution? - How did Cardinal Health achieve steady growth through fiscal years 2024 and 2025? - Why is transparency in financial reporting a key advantage for their med-surg business? - What role do private-label brands play in a modern healthcare sourcing strategy? - How does Cardinal Health fit into a dual-source strategy against its top competitors? - What are the key criteria for selecting a "Big-Three" distributor in 2025? - How can integrated analytics and a national footprint benefit healthcare providers? Navigating the U.S. market requires a robust distribution strategy, as exemplified by leaders like Cardinal Health. For MedTech and IVD companies looking to expand globally, a strong regulatory partner is just as critical. Pure Global offers end-to-end consulting solutions, from developing efficient regulatory pathways to acting as your local representative in over 30 markets. Our advanced AI tools streamline the creation of technical dossiers and provide crucial market insights, ensuring your products reach new territories faster. Let us help you build a seamless global market access strategy. Visit us at https://pureglobal.com, contact [email protected], or explore our FREE AI tools and database at https://pureglobal.ai.

This episode explores Medline Industries, the top medical-surgical distributor in the United States. We uncover the immense scale of its operations, its unique business model that combines distribution with in-house manufacturing, and the significant details surrounding its upcoming high-profile IPO planned for 2025, which is poised to be one of the year's largest listings. - What makes Medline the number one medical-surgical distributor in the U.S.? - How does Medline's manufacturing of its own products give it a competitive edge? - What is the scale of Medline's distribution network and product portfolio? - What are the key details surrounding Medline's planned 2025 IPO? - Why is Medline considered a potential $5 billion listing? - For whom is Medline the typical first call for medical supplies in the U.S.? - How does Medline maintain supply resilience and pricing leverage? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, streamlining global market access with local expertise and advanced AI. Whether you're a startup or a multinational, we develop efficient regulatory strategies, manage technical dossiers, and act as your local representative in over 30 markets. Our integrated approach allows a single registration process to unlock multiple countries. Leverage our technology-driven efficiency for your expansion. Contact Pure Global at [email protected], visit https://pureglobal.com, or explore our free AI tools and database at https://pureglobal.ai.

This episode explores the transformation of the U.S. hearing aid market following the FDA's landmark 2022 rule that established an over-the-counter (OTC) category. We analyze the impact on accessibility, device innovation, and affordability, while also examining the continued importance of the prescription hearing aid channel. The discussion covers early market analyses from 2024 and the outlook for 2025, highlighting the factors that make hearing aids a key medical device category. - What was the FDA's landmark hearing aid rule in 2022? - How did the creation of an OTC category change market access for consumers? - Why did so few people who needed hearing aids use them historically? - What technological innovations are emerging in OTC hearing aids? - What is the ongoing role of prescription hearing aids fitted by audiologists? - What do early 2024 and 2025 analyses reveal about the new market? - Why are hearing aids one of the most popular device categories for 2025? - How can manufacturers navigate this dual OTC and prescription market? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, streamlining global market access with local expertise and advanced AI. We act as your local representative in over 30 markets, developing efficient regulatory strategies and using AI to compile technical dossiers. From initial market research to post-market surveillance, our integrated approach helps you expand efficiently. Whether you're a startup or a multinational enterprise, Pure Global provides the solutions to get your innovations to patients faster. To learn more, visit us at https://pureglobal.com, contact [email protected], or explore our FREE AI tools and database at https://pureglobal.ai.

This episode explores the robust and growing U.S. market for Continuous Positive Airway Pressure (CPAP) and Automatic Positive Airway Pressure (APAP) devices used to treat obstructive sleep apnea (OSA). We delve into the key factors driving sustained, double-digit demand, including the high prevalence of OSA among American adults. The discussion also covers the maturation of the clinical and payer ecosystem, which now better supports long-term patient adherence through innovations like home sleep testing, tele-monitoring, and diverse mask options, ensuring the continued dominance of this essential home-use medical device. Key Questions: - Why is CPAP therapy considered the first-line treatment for obstructive sleep apnea? - How large is the estimated patient population for OSA in the United States? - What market trends are driving the sustained, double-digit demand for these devices? - How has the healthcare ecosystem evolved to overcome challenges with patient adherence? - What role are consumer wearables playing in the future of sleep apnea diagnosis? - Are there emerging alternative therapies to CPAP/APAP devices? - What makes the CPAP market a unique example of a popular home-use medical device? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, streamlining global market access with local expertise and advanced AI. Our services cover the entire product lifecycle, from initial regulatory strategy and technical dossier submission to post-market surveillance. By leveraging our global network and technology-driven efficiency, we help companies navigate complex regulatory landscapes and accelerate their entry into over 30 markets worldwide. To learn how we can help you access global markets faster, visit us at https://pureglobal.com/, contact [email protected], or explore our FREE AI tools and database at https://pureglobal.ai.

This episode explores the dynamic landscape of Cardiac Implantable Electronic Devices (CIEDs), including pacemakers, ICDs, and CRT devices. We discuss why these devices are now a routine therapy, driven by an aging population and technological advancements. We cover key innovations like leadless technology, remote monitoring, and MRI-conditional labeling, and examine market trends for 2024-2025, including conduction-system pacing, highlighting how these devices remain a cornerstone of modern cardiology. Key Questions: - What factors are driving the widespread adoption of CIEDs? - How many new CIEDs are implanted annually in the U.S. alone? - What are the most significant recent innovations in pacemaker and ICD technology? - How does cloud-based remote monitoring improve patient outcomes and clinic efficiency? - What does the large existing patient base mean for the future of the CIED market? - What key trends for 2024–2025 are shaping the next generation of cardiac implants? - Why are these devices considered a mainstay for treating arrhythmias and heart failure? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, helping you navigate the complex global market for devices like CIEDs. We develop efficient regulatory strategies and use advanced AI to compile technical dossiers for submission, streamlining your path to market access. Whether you're a startup or a multinational enterprise, our local experts across 30+ markets can act as your representative and ensure continuous compliance. To accelerate your global expansion and access free AI tools and regulatory databases, visit us at https://pureglobal.ai or contact [email protected].

This episode delves into the U.S. market for hip and knee replacement implants, analyzing data from the American Joint Replacement Registry’s 2024 report. We explore the procedural volumes, key market trends for 2025 such as the shift to outpatient settings, the rise of robotics, and the growing demographic of younger patients seeking joint arthroplasty to maintain active lifestyles. - What does the American Joint Replacement Registry's 2024 report reveal about the U.S. market? - Why do knee replacements constitute nearly half of all major joint arthroplasty cases? - How is the industry-wide shift to outpatient settings impacting implant manufacturers? - What role are robotics and cementless fixation playing in modern orthopedic surgery? - Why are younger patients increasingly seeking hip and knee implants? - What are the dominant market dynamics for orthopedic devices in the U.S. for 2025? - How can medical device companies adapt their regulatory strategy to these evolving trends? Pure Global provides comprehensive regulatory consulting for MedTech and IVD companies seeking to accelerate global market access. We combine in-country expertise across more than 30 markets with advanced AI and data tools to streamline your journey. From developing regulatory strategy and compiling technical dossiers to acting as your local representative and ensuring post-market compliance, we offer end-to-end solutions. Our unique 'single process, multiple markets' approach maximizes efficiency, helping startups and multinational enterprises alike. To learn how we can help you navigate the global landscape, visit us at https://pureglobal.com/, contact [email protected], or explore our FREE AI tools and database at https://pureglobal.ai.

This episode explores the rapid adoption of Continuous Glucose Monitors (CGMs) and insulin pumps in the United States, detailing how changes in reimbursement policy, specifically from the Centers for Medicare & Medicaid Services (CMS) in April 2023, transformed these devices from niche products to mainstream standards of care for a growing number of people with both type 1 and type 2 diabetes. - How did CGM technology transition from a niche to a mainstream medical device in the U.S.? - What critical role did CMS play in expanding market access for CGMs? - Why are more people with type 2 diabetes now using CGMs than those with type 1? - What specific policy change in April 2023 opened the door for millions more patients? - How have both public and commercial insurance plans fueled the CGM boom? - What technological advancements are driving competition among manufacturers in 2025? - How are policy, technology, and data combining to reshape modern diabetes care? Navigating complex regulatory environments like the U.S. requires deep expertise. Pure Global offers end-to-end consulting for MedTech and IVD companies, leveraging local experts and advanced AI to streamline global market access. We develop efficient regulatory strategies, manage technical dossier submissions, and act as your local representative to ensure your product gets to market quickly and stays compliant. Whether you are a startup or a multinational, our solutions are tailored to your needs. Contact us at [email protected], visit our website at https://pureglobal.com, or explore our free AI tools and database at https://pureglobal.ai.

This episode explores how MedTech companies are leveraging advanced AI agents to overcome traditional hurdles in global medical device regulation. We discuss the shift from slow, manual processes to an automated, intelligent strategy that monitors real-time regulatory changes, streamlines technical dossier preparation for over 30 markets, and accelerates time-to-market by up to 75%, transforming the landscape for startups and multinational enterprises alike. - How can AI agents monitor real-time regulatory changes across 30+ countries? - What are the biggest challenges in traditional global medical device registration? - Can AI really reduce the time-to-market for a new medical device by 75%? - How does an AI-powered approach minimize submission rejections from authorities like the FDA or Notified Bodies? - What specific tasks in dossier preparation can be automated with AI? - How can you leverage your existing technical documentation for faster entry into new markets? - What does the future of MedTech regulatory affairs look like with the rise of AI? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, leveraging AI to streamline global market access. Our experts, combined with powerful data tools, help you navigate complex landscapes across 30+ markets, from the US and EU to Asia. We develop efficient regulatory strategies, use AI to compile technical dossiers, and act as your local representative to get your products to market faster. If you're looking to accelerate your global expansion, visit us at https://pureglobal.com, contact [email protected], or explore our FREE AI tools and database at https://pureglobal.ai.

This episode explores real-world case studies of MedTech companies using advanced AI agents to accelerate FDA submissions, expand into multiple European markets simultaneously, and maintain compliance in complex regions like Japan. We break down how AI is reducing preparation times by 70%, driving revenue growth by 300%, and preventing costly regulatory missteps for Class II, Class III, and diagnostic devices. - How can AI reduce FDA submission preparation time by over 70%? - What tools help companies identify and enter 8 new European markets at once? - How did one company achieve a 300% revenue increase in 18 months through regulatory strategy? - What is the most effective way to monitor real-time regulation changes in key markets like Japan? - How can AI agents improve the accuracy and compliance confidence of your regulatory team? - What proactive measures can prevent costly recalls from missed regulatory updates? - What are the tangible benefits of AI for companies with Class II and Class III medical devices? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, leveraging AI and local expertise to accelerate global market access. Our AI-powered tools streamline technical dossier preparation, our market access agents identify the most efficient registration pathways, and our compliance monitors provide real-time updates to protect your market presence. We act as your local representative in over 30 markets, turning a complex global strategy into a streamlined process. To learn how we can help your company expand, visit us at https://pureglobal.com, contact [email protected], or explore our FREE AI tools and database at https://pureglobal.ai.

This episode details the full range of medical devices and regulatory services supported for global market access. We explain our expertise with both MedTech and In-Vitro Diagnostic (IVD) products, from simple tools to complex software. The discussion covers the complete lifecycle of our services, including initial regulatory strategy, AI-powered technical submissions, local representation in over 30 markets, post-market surveillance, and continuous compliance monitoring tailored for startups, scaleups, and large multinational enterprises. - What specific types of MedTech and IVD devices do you support? - How can a 'Single Process, Multiple Markets' approach accelerate global expansion? - What is the role of AI in streamlining technical dossier submissions? - Which services are critical for maintaining market compliance after a product is launched? - How is regulatory support tailored for startups versus multinational corporations? - What does an end-to-end regulatory solution include? - Why is a local, in-country representative essential for market access? - How can you stay ahead of constantly changing international regulations? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, streamlining global market access with a unique blend of local expertise and advanced AI. Our services cover the entire product lifecycle, from regulatory strategy and technical dossier submissions to post-market surveillance and quality assurance. By acting as your local representative in over 30 markets, we enable a 'Single Process, Multiple Markets' approach, accelerating your expansion. Discover how our technology-driven solutions can help your company grow. Visit https://pureglobal.com, contact us at [email protected], or explore our FREE AI tools and database at https://pureglobal.ai.

This episode explores how regulatory strategies for MedTech and IVD devices must adapt to a company's growth stage. We discuss the unique challenges and tailored solutions for startups seeking initial market entry, scaleups planning international expansion, and multinational enterprises managing complex global portfolios. Learn how a strategic approach, from agile guidance to AI-powered compliance, can support your company at every step of its journey. - How do the regulatory challenges of a startup differ from those of a multinational enterprise? - What should a fast-growing scaleup look for in a global regulatory partner? - Can a single registration process be leveraged to enter multiple international markets? - How can AI and data tools streamline technical dossier submission and market research? - What are the key strategies for maintaining compliance across a diverse global product portfolio? - Are there cost-effective ways for startups to navigate complex regulations in the EU, US, or Asia? - How can a company choose the right international markets for strategic expansion? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies at every stage of growth. Whether you're a startup needing agile guidance, a scaleup expanding globally, or a multinational enterprise optimizing a complex portfolio, our solutions are designed for your specific needs. We leverage our local expertise in over 30 markets and advanced AI data tools to accelerate your growth, from initial strategy and technical dossier submission to post-market surveillance. Contact Pure Global at [email protected], visit us at https://pureglobal.com, or explore our FREE AI tools and database at https://pureglobal.ai.

This episode explores the evolution of regulatory consulting for MedTech and IVD devices. We contrast the traditional, fragmented consulting model with Pure Global's integrated, technology-driven approach. Discover how AI, a unified global-local team, and an end-to-end service model are revolutionizing how companies achieve faster, more efficient market access in over 30 countries. - Why does the traditional multi-consultant model often lead to higher costs and delays? - How can a "single process, multiple markets" strategy accelerate your global expansion? - What role does Artificial Intelligence play in compiling technical dossiers and submissions? - How does having dedicated local offices differ from a network of third-party agents? - Can you leverage one partner for everything from initial strategy to post-market surveillance? - What advantages does a database of over 5 million products offer for clinical data analysis? - How is a technology-driven approach changing regulatory affairs from a cost center to a strategic advantage? Pure Global offers end-to-end regulatory solutions for MedTech and IVD companies, combining local expertise with advanced AI to streamline global market access. Our integrated approach enables a single registration process for multiple markets, from the US and EU to Asia. We support startups and multinationals with regulatory strategy, technical submissions, and post-market surveillance. For faster, technology-driven market access, visit https://pureglobal.com or contact [email protected]. Explore our free AI tools and regulatory database at https://pureglobal.ai.

This episode explores how MedTech and IVD companies can overcome the complexities of international expansion. We discuss a unified, technology-driven approach to registering medical devices in over 30 global markets simultaneously, covering everything from initial regulatory strategy and market selection to the role of local representation and AI-powered technical dossier submissions. Key Questions: - How can you enter 30+ global MedTech markets with a single registration process? - What are the critical first steps in developing a global regulatory strategy? - Why is local representation essential for market access in countries like Brazil or South Korea? - How can AI accelerate the creation and submission of your technical dossiers? - What's the key to selecting the most promising international markets for your device? - How do you maintain compliance after your product is approved abroad? - Can one unified approach work for both startups and multinational corporations? Pure Global provides end-to-end regulatory consulting solutions for MedTech and IVD companies, streamlining access to over 30 global markets. We combine local expertise with advanced AI to manage the entire product lifecycle, from regulatory strategy and market selection to technical dossier submission and post-market surveillance. Our unique 'Single Process, Multiple Markets' approach simplifies expansion, saving you time and resources. Whether you're a startup or a multinational, we act as your local representative to ensure a smooth path to commercialization. For expert guidance, visit https://pureglobal.com/, contact [email protected], or explore our FREE AI tools and database at https://pureglobal.ai.

This episode breaks down the crucial differences between free and paid resources in the complex world of medical device market access. We explore what you can achieve with publicly available information from regulatory bodies and when it becomes essential to invest in expert services for strategy, submission, and reimbursement to ensure a successful product launch. - What essential regulatory information is available for free? - Are government websites and databases sufficient for building a full market entry strategy? - When does it become critical to invest in paid consulting and local representation? - How can you determine the return on investment for paid market access services? - What are the hidden costs and risks of relying solely on free resources? - Why is navigating reimbursement and Health Technology Assessment (HTA) bodies impossible without expert support? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies. We combine local expertise in over 30 markets with advanced AI tools to streamline global market access, from initial strategy and technical dossier submission to post-market surveillance. Our integrated approach allows a single registration process to unlock multiple markets, saving you time and resources. Whether you are a startup or a multinational enterprise, our solutions are tailored to get your innovations to patients faster. Contact us at [email protected], visit our website at https://pureglobal.com, or explore our free AI tools and database at https://pureglobal.ai.

This episode explores the critical distinction between standalone AI SaaS tools and a fully integrated, service-based approach for MedTech global market access. We dissect why expensive software alone often falls short and how combining advanced AI with on-the-ground human expertise, local representation, and end-to-end regulatory services provides a more efficient and effective path to launching and maintaining products in over 30 international markets. Key Questions: - Is your expensive AI SaaS tool actually accelerating your global market access? - What is the critical gap most standalone software solutions leave for your regulatory team? - How can a single registration process unlock access to over 30 countries? - What does an integrated service model offer that a pure SaaS platform cannot? - Why is local, human expertise still irreplaceable in the age of AI? - How can AI be used to empower a global team rather than just automate a single task? - What should you look for in a true global regulatory partner? Pure Global offers the end-to-end solution discussed in this episode. We don't just sell software; we provide a complete partnership for MedTech and IVD companies. Our approach combines advanced AI for efficiency with the critical expertise of local representatives in over 30 markets. From initial regulatory strategy and technical dossier submission to post-market surveillance, we streamline your entire global market access journey. Let us handle the complexities so you can focus on innovation. Contact us at [email protected], visit https://pureglobal.com, or explore our FREE AI tools and database at https://pureglobal.ai to see the difference.

This episode explores the strategies and regulatory hurdles involved in bringing medical devices to underserved and emerging global markets. We discuss how to leverage existing approvals, the critical role of local representation, and the use of technology to streamline multi-country submissions, focusing on promising regions like Latin America and Southeast Asia. Key Questions: - How can you leverage your existing US or EU approvals to enter new regions? - What are the primary regulatory hurdles in Latin American and Southeast Asian markets? - Why is local representation critical for success in underserved economies? - How can technology streamline submissions for multiple, non-harmonized markets? - What is the first step in identifying the most promising underserved markets for your device? - Is it possible to use a single registration process to access dozens of countries? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, streamlining global market access with a unique blend of local expertise and advanced AI. We help you develop efficient regulatory strategies, act as your local representative in over 30 markets, and use AI to compile technical dossiers for faster submissions. Our integrated approach allows a single registration process to unlock multiple international markets simultaneously. To accelerate your global expansion and access our FREE AI tools and regulatory database, visit us at https://pureglobal.ai or contact our team at [email protected].

This episode explores how Artificial Intelligence is revolutionizing the medical device registration process, breaking down financial barriers and enabling broader global market access. We discuss the shift from costly, manual submissions to an efficient, technology-driven model that allows MedTech companies of all sizes to bring life-saving innovations to patients worldwide. Learn how AI is not just a tool for efficiency but a force for democratizing global healthcare access. Key Questions: - How can AI drastically reduce the cost of medical device registration? - What are the traditional barriers preventing MedTech companies from entering global markets? - How does lowering registration costs impact patient access to life-saving devices? - Can AI help you bring 10 times more products to 10 times more countries? - Which global markets can be navigated using AI-powered regulatory intelligence? - What specific tasks in the regulatory submission process can be automated? - How is technology making global compliance accessible for startups and smaller companies? Pure Global offers end-to-end regulatory solutions for MedTech and IVD companies, leveraging AI and local expertise to accelerate global market access. We help you develop regulatory strategies, compile technical dossiers with advanced AI, and act as your local representative in over 30 markets. Our goal is to make global expansion efficient and affordable, from initial strategy to post-market surveillance. Visit us at https://pureglobal.com, contact [email protected], or explore our FREE AI tools and database at https://pureglobal.ai to start your journey.

This episode explores the transformative impact of free AI-powered tools on the medical device industry. We discuss how making regulatory intelligence and global device databases accessible at no cost is breaking down financial barriers, enabling MedTech companies to expand their reach into new international markets more efficiently and affordably. This shift promises to accelerate the availability of life-saving technologies to patients around the world. - How is Artificial Intelligence revolutionizing the MedTech regulatory landscape? - What if you could access global medical device registration databases for free? - Can AI genuinely lower the cost of market entry for life-saving devices? - What specific AI-powered tools are now available to streamline compliance in over 30 markets? - How can your company leverage free AI for device classification and regulatory pathway analysis? - What is the vision behind making core regulatory AI agents completely free? - How does this shift impact market access in regions like South America, Asia, and Africa? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, leveraging advanced AI to streamline global market access. We help you identify the best markets, develop efficient regulatory strategies, and use AI to compile and submit technical dossiers. Our integrated approach allows a single registration process to unlock multiple international markets, supported by local experts in over 30 countries. Whether you're a startup or a multinational enterprise, our technology-driven solutions accelerate your time-to-market. Explore our free AI tools and databases at https://pureglobal.ai, visit our website at https://pureglobal.com, or contact us at [email protected].

This episode provides a detailed overview of Colombia's foundational medical device regulation, Decree 4725 of 2005. We explore the critical role of INVIMA, the risk-based classification system, key submission requirements for market approval, and post-market surveillance obligations for MedTech and IVD manufacturers looking to enter the Colombian market. Key Questions - What is Decree 4725 and why is it essential for market access in Colombia? - How does INVIMA classify medical devices based on risk? - What are the core components of a technical dossier for submission in Colombia? - Is a local legal representative required to register a medical device in Colombia? - What are a manufacturer's post-market surveillance responsibilities under Colombian law? - How does Colombia's regulatory framework compare to others globally? - What are the first steps to begin the medical device registration process in Colombia? Pure Global offers end-to-end regulatory consulting solutions for MedTech and IVD companies targeting Latin America. We act as your local representative in Colombia, developing efficient regulatory strategies to navigate INVIMA's requirements under Decree 4725. Our experts and advanced AI tools streamline the compilation and submission of your technical dossier, helping you access the Colombian market faster. Whether you are a startup or a multinational, we ensure your market entry and post-market activities are fully compliant. Contact us at [email protected], visit https://pureglobal.com, or explore our FREE AI tools and database at https://pureglobal.ai.

This episode provides a detailed overview of Mexico's Technovigilance requirements for medical devices under COFEPRIS regulation NOM-240-SSA1-2012. We explore the mandatory post-market surveillance system, including the roles of the Sanitary Registration Holder, adverse event reporting timelines, and the documentation required for registration renewal. We also discuss the significant updates proposed in the draft 2024 version of the standard, which will impact software devices and distributor obligations. - What is Technovigilance and why is it mandatory for medical devices in Mexico? - Who is responsible for reporting adverse events to COFEPRIS? - What are the specific reporting deadlines for serious and non-serious incidents? - How does post-market surveillance impact the 5-year renewal of your sanitary registration? - What is the function of a Mexico Registration Holder (MRH) in the Technovigilance process? - What key changes are introduced in the draft PROY-NOM-240-SSA1-2024? - Will Software as a Medical Device (SaMD) be covered under the new Technovigilance rules? - What are the core components of a compliant Technovigilance unit? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, streamlining global market access. We act as your local representative in over 30 markets, including Mexico, managing your registration and Technovigilance obligations. Our experts develop efficient regulatory strategies and use advanced AI to compile technical dossiers, ensuring compliance with bodies like COFEPRIS. Let us help you maintain your market presence with continuous regulatory monitoring and post-market surveillance support. For a seamless path to market, contact us at [email protected], visit our website at https://pureglobal.com, or explore our free AI tools at https://pureglobal.ai.

This episode provides a critical update on Mexico's new mandatory standard for medical device labeling, NOM-137-SSA1-2024. The host breaks down the key changes from the previous 2008 version, including the strict Spanish language requirement, new provisions for electronic labeling and Software as a Medical Device (SaMD), and updated rules for symbols and date formats. We cover the official publication and effective dates, helping manufacturers understand the timeline for compliance to maintain market access in Mexico. - What is the new mandatory labeling standard for medical devices in Mexico? - When does NOM-137-SSA1-2024 officially come into effect? - Are English labels still acceptable in Mexico under the new regulation? - How does the new standard address electronic labeling and Software as a Medical Device (SaMD)? - What are the specific requirements for displaying expiration dates and using symbols? - What happens if my device labeling is not compliant by the deadline? - How does this 2024 update differ from the previous NOM-137-SSA1-2008? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies. We streamline global market access using a blend of local expertise and advanced AI. Whether you're navigating Mexico's new NOM-137 standard or expanding into any of our 30+ markets, our team can help with regulatory strategy, technical dossier submission, and post-market surveillance. Our technology-driven approach ensures efficiency and accuracy, helping you get to market faster. Explore our services at https://pureglobal.com, contact us at [email protected], or access our FREE AI tools and database at https://pureglobal.ai.

This episode provides a detailed overview of Mexico's mandatory Good Manufacturing Practices (GMP) standard, NOM-241-SSA1-2021. The host breaks down the key requirements for medical device manufacturers, including the implementation of a Quality Management System, risk management protocols, and alignment with ISO 13485. We discuss the standard's scope, its effective date, and the practical implications for companies seeking to enter or remain compliant in the Mexican market. Key Questions - What is NOM-241-SSA1-2021 and why is it critical for the Mexican market? - How does this standard impact the entire lifecycle of a medical device? - What are the core requirements of a compliant Quality Management System under NOM-241? - How does NOM-241 align with the international ISO 13485 standard? - Are you prepared for a GMP inspection by Mexican authorities? - What documentation is essential for demonstrating compliance? - When did this mandatory standard become fully effective? - Does this regulation affect foreign manufacturers importing into Mexico? Pure Global offers end-to-end regulatory consulting solutions for MedTech and IVD companies, combining local expertise with advanced AI to streamline global market access. We help you develop efficient regulatory strategies, compile technical dossiers, and act as your local representative in over 30 markets, including Mexico. Our technology-driven approach ensures you navigate complex standards like NOM-241 with confidence. For assistance with your market access needs, visit us at https://pureglobal.com, contact [email protected], or explore our FREE AI tools and database at https://pureglobal.ai.

This episode provides a detailed overview of Mexico's medical device regulations, focusing on the Reglamento de Insumos para la Salud. We explore the role of the regulatory authority, COFEPRIS, the risk-based device classification system, and the available registration pathways, including the Standard and Equivalency routes. The host also covers the crucial updates from the 5th edition of the Mexican Pharmacopoeia's supplement, which became effective in July 2023. - What is the primary regulation for medical devices in Mexico? - How does COFEPRIS classify medical devices based on risk? - What is the difference between the Standard and Equivalency registration routes? - Which foreign approvals can be used to expedite registration in Mexico? - What key changes were introduced in the July 2023 regulatory update? - What are the documentation and language requirements for a submission? - Why is a Mexico Registration Holder (MRH) necessary for foreign manufacturers? - What is the role of the NOM-241 standard in Mexico's QMS requirements? Pure Global offers end-to-end regulatory consulting solutions for MedTech and IVD companies, combining local expertise with advanced AI to streamline global market access. We act as your local representative in over 30 markets, including Mexico, developing efficient regulatory strategies and using AI to compile and submit technical dossiers. Our services ensure your products meet all local standards for a faster path to market. Contact us at [email protected], visit our website at https://pureglobal.com, or explore our free AI tools and database at https://pureglobal.ai to learn how we can accelerate your global expansion.

This episode provides a comprehensive overview of Mexico's foundational health regulation, the Ley General de Salud, and its impact on medical device market access. We explore the role and authority of the regulatory body, COFEPRIS, and break down the key requirements manufacturers must meet, from pre-market registration and GMP compliance to post-market technovigilance and import controls. Key Questions - What is the Ley General de Salud and why is it critical for MedTech companies? - How does COFEPRIS regulate medical devices in Mexico? - What are the essential components of Mexico's regulatory framework for medical devices? - Are foreign manufacturers required to have a local representative in Mexico? - What are Norma Oficial Mexicana (NOMs) and how do they apply to manufacturing? - What is "technovigilance" and what are the post-market requirements? - Does Mexico have a risk-based classification system for medical devices? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, streamlining global market access with a unique blend of local expertise and advanced AI tools. Our Market Access & Registration services help you identify the best markets, develop efficient regulatory strategies, and prepare technical dossiers for submission. Acting as your local representative in over 30 markets, we manage the entire registration process to get your product approved and ready for sale. Visit https://pureglobal.com/, email us at [email protected], or explore our FREE AI tools and database at https://pureglobal.ai to learn more.

This episode provides a detailed analysis of Brazil's RDC 687/2022, a critical regulation from ANVISA governing Good Manufacturing Practices (GMP) certification for Class III and IV medical device manufacturers. We explore the key requirements, audit procedures, and documentation needed to secure the mandatory CBPF certificate, highlighting the changes from the previous RDC 183/2017 and what international manufacturers must do to successfully enter the Brazilian market for high-risk devices. Key Questions: - What is ANVISA's RDC 687/2022 and who does it apply to? - How does this regulation impact manufacturers of Class III and IV medical devices? - What are the mandatory steps to obtain GMP certification in Brazil? - What replaced the previous RDC 183/2017 regulation, and when? - How long is the Brazilian GMP certificate valid for? - What kind of documentation is required for the submission to ANVISA? - Why is this certification a prerequisite for market entry in Brazil? Navigating regulations like Brazil's RDC 687/2022 is where Pure Global excels. We offer end-to-end regulatory consulting for MedTech and IVD companies, streamlining global market access with local expertise and AI tools. Our team acts as your local representative in Brazil and over 30 other markets, developing efficient pathways for ANVISA approval and using AI to compile technical dossiers. We manage submissions and ensure ongoing compliance so you can access markets faster. For comprehensive support, contact us at [email protected], visit https://pureglobal.com, or explore our FREE AI tools and database at https://pureglobal.ai.

This episode provides a detailed overview of Brazil's key technovigilance regulations for medical devices, RDC 67/2009 and RDC 551/2021. We explore the mandatory requirements for post-market surveillance, the critical role of the Brazilian Registration Holder (BRH), and the specific, strict timelines set by ANVISA for reporting adverse events, malfunctions, and field safety corrective actions to ensure continued compliance and patient safety in the Brazilian market. - What is the primary purpose of Brazil's RDC 67/2009? - How does RDC 551/2021 complement the requirements of RDC 67/2009? - Who is ultimately responsible for technovigilance reporting to ANVISA? - What are the specific reporting timelines for different types of adverse events? - What happens if a serious adverse event occurs outside of Brazil with a device sold in the country? - Are malfunctions that haven't caused harm required to be reported? - Why is a proactive post-market surveillance system crucial for market access in Brazil? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, streamlining global market access. We act as your local representative in over 30 markets, including Brazil, ensuring your post-market surveillance and technovigilance systems are fully compliant with ANVISA's requirements. Our experts manage adverse event reporting and field safety corrective actions, navigating complex timelines so you can maintain market presence securely. Leveraging advanced AI, we make compiling and managing technical documentation efficient and accurate. For expert guidance on entering and staying in the Brazilian market, contact us at [email protected], visit https://pureglobal.com/, or explore our FREE AI tools and database at https://pureglobal.ai.

This episode explores Brazil's key regulation for medical device and IVD manufacturers, ANVISA RDC 665/2022. We break down the Brazilian Good Manufacturing Practices (BGMP) requirements, its alignment with international standards like ISO 13485, its replacement of the former RDC 16/2013, and its crucial integration with the Medical Device Single Audit Program (MDSAP) for streamlining market entry. Key Questions: - What is ANVISA RDC 665/2022 and who does it apply to? - How does this resolution change the requirements from the old RDC 16/2013? - What are the core principles of Brazilian Good Manufacturing Practices (BGMP)? - How does RDC 665/2022 align with global standards like ISO 13485 and FDA QSR? - Can an MDSAP audit be used to achieve BGMP certification in Brazil? - What are the key dates associated with the implementation of RDC 665/2022? - Why is BGMP compliance a mandatory step for selling medical devices in Brazil? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, leveraging local expertise and advanced AI to streamline global market access. We act as your local representative in over 30 markets, developing efficient regulatory strategies and using AI to compile and submit technical dossiers. Our integrated approach allows a single registration process to access multiple markets, supported by our global reach and technology-driven efficiency. Whether you are a startup or a multinational, we provide scalable solutions to get your innovations to market faster. Contact us at [email protected], visit https://pureglobal.com/, or explore our FREE AI tools and database at https://pureglobal.ai/.

This episode provides a detailed analysis of Brazil's new IVD regulation, ANVISA RDC 830/2023, which was implemented in June 2024. We explore the critical changes to risk classification systems, which align with international standards and result in the up-classification of many devices. The discussion covers the impact on regulatory pathways, technical documentation, and labeling, offering essential insights for manufacturers to ensure continued market access in Brazil. - What is Brazil's new RDC 830/2023 for IVD devices? - When did this new ANVISA regulation take effect? - How does the new risk classification system impact IVD manufacturers? - Why are many IVD devices being moved to higher risk classes in Brazil? - What is the difference between the 'notificação' and 'registro' pathways? - What are the new labeling requirements under RDC 830/2023? - How should your company prepare for these regulatory changes in Brazil? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, streamlining global market access. With Brazil's new RDC 830/2023 creating significant shifts, our local experts and advanced AI tools are essential for navigating the updated risk classifications and registration requirements. We act as your local representative in over 30 markets, including Brazil, developing efficient regulatory strategies and compiling technical dossiers to ensure compliance and speed to market. Let us help you navigate this changing landscape. Contact us at [email protected], visit https://pureglobal.com, or explore our FREE AI tools and database at https://pureglobal.ai.